



GILUPI extends Patent Portfolio - New European Patent granted

GILUPI GmbH announced that the company was granted a European patent protecting the unique and innovative GILUPI technology for the capture of circulating cancer cells (CTCs) and further applications.

The European Patent Office (EPO) issued patent EP2807979 B1 entitled "Detection device for in-vivo and/or in-vitro enrichment of sample material". The patent describes a functionalized structured medical wire for the enrichment of sample material. The technology is already being used in clinical settings on national and international levels.

"With the issuance of this new European Patent we are further strengthening GILUPI's superior intellectual property position in the area of CTC enrichment. The commercialization of this IP is already ongoing and we will continue to leverage our IP with new products that are currently in development." said Dr. Christian Jurinke, CEO of GILUPI.

GILUPI's patent portfolio consists of 11 patent families and further patent applications that are currently subject to examination procedures for a number of inventions.

About GILUPI GmbH

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies become increasingly important in personalized medicine. The identification of the right drug for the individual patient is today's challenge in clinical practice. To address this medical need, the GILUPI CellCollector[®] is used to enrich rare cells by immunocapture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers and patient positivity rates in various cancer types. Applying diagnostic analyses ranging from immunostaining, DNA- and RNA-based methods, isolated cells can be characterized and/or analyzed down to a molecular level.

The GILUPI CellCollector[®] is the first in vivo CTC isolation product worldwide that is CE approved.

For further information visit www.gilupi.com